Service the qualified state — yours, and your customers'.
Pharma instrument OEMs — bioprocess, chromatography, mass spec, balances — sell calibrated, qualified equipment into GMP environments. Your customers run formal supplier-qualification audits referencing GAMP 5, Annex 11, Part 11, Annex 15, and USP <1058>. Your internal QMS sits under ISO 9001 (and ISO 13485 if you're a combination med/pharma vendor). Wēlr is the substrate underneath both — your supplier-audit posture and your post-sale service evidence on one record.
Four gaps your customers' supplier audits keep finding.
- 01
Customer supplier audits are a multi-week document hunt — every visit.
Each pharma customer's QA team runs a formal supplier qualification audit. They want design controls, complaint handling, change-control history, calibration traceability, SDLC attestation, and Part 11 / Annex 11 evidence — packaged in their format. The 'vendor validation portfolio' is rebuilt for every visit because no single system holds it.
- 02
Requalification windows shift; your customer's QA team expects you to know.
Firmware updates, reagent / consumable lot changes, and configuration changes shift the requalification window. Most service organizations track them by spreadsheet, per customer. The customer's QA team finds the gap during their own audit and writes the supplier finding.
- 03
Field service evidence sits in the FSE's notebook.
Site visits are documented as PDF reports filed against a ticket. The link to the equipment's qualified-state record happens by hand, weeks later. Part 11 e-signatures are enforced by FSE training, not architecture.
- 04
Cross-region service teams reconcile by spreadsheet.
EMEA produces Annex 11 evidence; the US produces Part 11 extracts; APAC fields PIC/S supplier audits. Regional dispatch, qualification verification (training · geography · sponsor-of-record), and parts inventory live in regional silos. Cross-region intelligence is a quarterly slide deck.
Four primitives. One dual-posture record.
Vendor validation portfolio — living, per product line
Design controls, change-control history, CAPA, calibration traceability, SDLC attestation, and supplier-audit evidence share one append-only record per product line. The 'Validation Compliance Package' your customer's QA team asks for is the system, not a project. Updated automatically as firmware releases ship.
Qualified-state lifecycle per instrument (your customers' posture)
IQ / OQ / PQ packages, change-control history, calibration certificates, and service events share one append-only record per instrument — across every customer site. Lifecycle phase (IQ Complete · OQ Complete · PQ In Progress · Re-qualification Due) is the system's truth, not a calendar entry.
Part 11 e-signature substrate
Append-only audit log, structural separation of duties, electronic signatures bound to verified identity at the API and database — enforced architecturally, not by FSE training. Annex 11 supplier-assessment evidence is the same substrate, presented differently.
Regional dispatch with qualification gates
Technician training, geography clearance, and sponsor-of-record approvals are first-class attributes. Dispatch fails closed if the qualification isn't valid. Cross-region parts and reliability intelligence become operational, not anecdotal.
Why not build it, or extend the CMMS?
Most pharma-instrument OEMs face the same three options. Build the platform in-house (an 18–24 month project; specialized regulatory architecture; a service team that has to ship while engineering builds). Extend a generic CMMS or service-cloud product (no qualified-state model; no Part 11 substrate; no living vendor-validation portfolio). Or Wēlr.
| Capability | Wēlr | Build in-house 18-24 mo · 8 engineers · ~$4M | Generic CMMS / FSM ServiceMax · Salesforce FS · Maximo |
|---|---|---|---|
| Living vendor validation portfolio per product line | Structural — built in | Custom architecture required | Bolt-on document store |
| Customer-side GAMP 5 / Part 11 / Annex 11 evidence | Architecturally enforced | 12+ months to build | FSE-process enforced, not architectural |
| Qualified-state per instrument across customers | First-class data model | Specialized schema work | Not modeled |
| Customer-facing compliance portal | Configuration, not a build | 12+ months to build | Not available |
| Time to first field engineer dispatch | Weeks | 2+ years | Weeks, but limited |
Vendor validation portfolio, per product line — living, audit-ready.
Your customer's QA team runs to a vendor-validation expectation. When they audit you, they want the validation compliance package on the instrument they bought — design controls, GAMP categorization, lifecycle status by phase, SDLC attestation, Annex 11 supplier assessment — kept current as firmware ships. Wēlr maintains that package as a living record, per product line and per site, not as a Word document rebuilt for every visit.
- Lifecycle phase per instrument · IQ / OQ / PQ Complete · Re-qualification Due
- GAMP 5 categorization per product line — your declaration, inherited at every site
- 21 CFR Part 11 audit trail + Annex 11 supplier-assessment evidence on the same record
- Updated automatically when firmware ships, configuration changes, or service events log
If any of these are true, we should talk.
- ✓Your field service evidence flows through PDFs filed against tickets — not into the equipment's qualified-state record.
- ✓Your customers' QA teams are asking for Part 11 audit-trail extracts or Annex 11 supplier assessments, and your team produces them in Word.
- ✓Your EMEA team is producing Annex 11 evidence, your US team is producing Part 11 extracts, your APAC team is fielding PIC/S supplier audits — and you reconcile the formats by spreadsheet.
- ✓Your VP of Sales keeps asking for a customer-facing compliance portal, and your CTO has scoped it at $3M+ / 8 engineers / 18 months.
- ✓A major pharma customer issued a supplier finding in the last cycle, and the root cause was evidence you couldn't reconstruct inside the response window.
A small founding cohort is shaping Wēlr for lab & instrument oems.
Founding partners get preferential pricing, a direct line to engineering, and meaningful influence over the Pharma & life sciences roadmap. Limited to a small cohort per vertical.
- Preferential pricing
- Direct line to engineering
- Roadmap influence
- Limited cohort
Ready to stop stitching service evidence together?
If your team is juggling PDFs, support packages, work orders, customer updates, and QA evidence across five systems, Wēlr is worth a look.
Welr LLC · Delaware